First Prospective Study of TKI Ponatinib Shows Benefit in Ph+ALL First Prospective Study of TKI Ponatinib Shows Benefit in Ph+ALL

The study findings add new insights, but also raise new questions, about the best treatment approach for Philadelphia chromosome-positive acute lymphoblastic leukemia.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news